Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LNPEP | Q9UIQ6 | 4/20 | 0.49 |
| ▸ | ANPEP | P15144 | 3/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.47 |
| ▸ | F2 | P00734 | 4/20 | 0.45 |
| ▸ | GLP1R | P43220 | 3/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30874946 | 0.90 | GLP1R (0.52) | OPRD1F2GLP1R | |
| SCHEMBL30874967 | 0.90 | GLP1R (0.52) | OPRD1F2GLP1R | |
| SCHEMBL30670300 | 0.89 | LNPEP (0.54) | LNPEPANPEP | |
| SCHEMBL30510653 | 0.88 | GLP1R (0.51) | OPRD1OPRM1GLP1ROPRK1 | |
| SCHEMBL30662034 | 0.86 | GLP1R (0.53) | OPRD1F2GLP1R | |
| SCHEMBL30510650 | 0.86 | OPRD1 (0.49) | LNPEPANPEPOPRD1OPRM1GLP1R | |
| SCHEMBL30874972 | 0.85 | OPRD1 (0.53) | OPRD1OPRM1GLP1ROPRK1 | |
| SCHEMBL30996216 | 0.85 | KISS1R (0.51) | OPRD1F2GLP1R | |
| SCHEMBL31450045 | 0.85 | KISS1R (0.51) | OPRD1F2GLP1R | |
| SCHEMBL30030378 | 0.85 | KISS1R (0.51) | OPRD1F2GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240197815-A1 | METHODS AND COMPOSITIONS FOR IMPROVING VISUAL FUNCTION IN OCULAR DISEASES AND DISORDERS | ONL THERAPEUTICS, INC. | 2024-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240197815-A1 | METHODS AND COMPOSITIONS FOR IMPROVING VISUAL FUNCTION IN OCULAR DISEASES AND DISORDERS | PDE6C, UACA, EYA3 | LNPEP 124/4885ANPEP 252/4885OPRD1 4615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.